the report was great, no surprises, but I think the positive effects are limited because at the end of the day Antibe needs a BIG Sugar DADDY. Until that happens, blastoff isn't going to happen.
I think phase IIC will help maintain price level but won't do much for the stock price.
The name recognition and details of any JV with big Pharma will dictate the price for Antibe. Nothing in the report today changes the positive future of Antibe but they are still a few steps, a few dollars and a big phase III away from a successful drug and nirvana for the stock.
A hot overall market with an appetite for biotech might change that but Antibe is still a little Canadian biotech in a US centric stock land.
Market Data 
Markets 
